Latest News

Media inquiries:

Rob May, Director of Marketing
rob.may@solstas.com
336-574-6873

Press Releases

Technical Bulletins

  • 2013-14 Flu Season Recommendations - Birmingham (11/1/13)

    The CDC has recommended vaccination for flu in individuals six months of age and older. The flu vaccine is developed annually targeted against the most active flu strains predictive for the season. However, other factors including a patient's weak immune system response, exposure to non-covered flu strains and other infectious agents including, but not limited to, Mycoplasma pneumoniae, adenovirus, respiratory syncytial virus, rhinovirus and parainfluenza virus may cause flu or flu-like symptoms following exposure.

    Read More
  • 2013-14 Flu Season Recommendations - Greensboro (11/1/13)

    The CDC has recommended vaccination for flu in individuals six months of age and older. The flu vaccine is developed annually targeted against the most active flu strains predictive for the season. However, other factors including a patient's weak immune system response, exposure to non-covered flu strains and other infectious agents including, but not limited to, Mycoplasma pneumoniae, adenovirus, respiratory syncytial virus, rhinovirus and parainfluenza virus may cause flu or flu-like symptoms following exposure.

    Read More
  • 2013-14 Flu Season Recommendations - Roanoke (11/1/13)

    The CDC has recommended vaccination for flu in individuals six months of age and older. The flu vaccine is developed annually targeted against the most active flu strains predictive for the season. However, other factors including a patient's weak immune system response, exposure to non-covered flu strains and other infectious agents including, but not limited to, Mycoplasma pneumoniae, adenovirus, respiratory syncytial virus, rhinovirus and parainfluenza virus may cause flu or flu-like symptoms following exposure.

    Read More
  • Hepatits C Viral RNA Quantification and Genotype (9/23/13)

    Solstas Lab Partners is pleased to announce the addition of the COBASAmpliPrep/COBAS TaqMan HCV Test, v2.0 and the Abbott Molecular RealTime HCV Genotype II assay to our testing menu. Both of these additions are FDA approved and intended for use as an aid in the management of HCV-infected individuals and will be enhancements to the existing HCV viral load and genotyping assays currently performed...

    Read More
  • Announcement: Rheumatoid Arthritis Screening Profile (7/2/13)

    Solstas Lab Partners is pleased to announce the addition of a new Rheumatoid Arthritis Screening Profile to our menu. This profile includes four tests which Solstas Lab Partners currently offers individually, in response to the recommendations of the American College of Rheumatology (ACR) for Rheumatoid Arthritis screening (1). The goal of earlier screening for Rheumatoid Arthritis (RA) is to prevent patients from developing the chronic, erosive disease state with earlier treatment. Certain laboratory tests can precede the clinical manifestation of RA by many years....

    Read More
  • PhenoPath - Clinical and Cancer Diagnostic Tests (7/2/13)

    Solstas Lab Partners is pleased to announce that we have aligned with PhenoPath Laboratories, a national reference pathology laboratory, to provide your practice with one solution for both your clinical and cancer diagnostic testing needs....

    Read More
  • Proper Collection of Urine Specimens (6/6/13)

    As with any type of laboratory specimen, certain criteria need to be met for proper collection and transportation of urine specimens. This ensures proper stability of the specimen and accurate test results. The type of urine collection container cups deployed by Solstas has a screw on lid....

    Read More
  • Specimen Tube Label Placement (6/5/13)

    Solstas Lab Partners is pleased to announce the introduction of new, highly-automated Sysmex hematology testing equipment at our Greensboro, N.C., core reference laboratory. These new FDA cleared hematology analyzers provide the latest in clinical hematology testing capabilities for your patients....

    Read More
  • Toxicology Department - Drug Testing Cutoff Changes (5/29/13)

    In association with the recent installation and validation of new liquid chromatography/tandem mass spectrometry (LC/MSMS) laboratory testing equipment, the Solstas Lab Partners Toxicology Department has recently introduced lower analytical cutoffs for detection and confirmation of common drugs of abuse. These lower analytical cutoffs may provide improved clinical information for the assessment of the patient status and correlation of immunoassay screening and confirmation test results....

    Read More
  • Respiratory Virus Panel Introduction (5/24/13)

    Respiratory viral infections represent one of the most common human infections and are responsible for a range of diseases including the common cold and pneumonia. Rapid diagnosis of respiratory infections enables health care providers to begin appropriate treatment, avoid unnecessary antibiotic use and laboratory tests, and control nosocomial spread of these infections....

    Read More
  • New CDC Guidelines for Levels of Lead in Children (5/17/13)

    Solstas Lab Partners is providing this Client Notification following recent information concerning new Centers for Disease Control and Prevention (CDC) guidelines for blood lead concentration in children....

    Read More
  • Introduction of Fourth Generation HIV Ag/Ab Combo Test for HIV Screening (5/16/13)

    Solstas Lab Partners is pleased to announce the commercial availability of a new 4th generation human immunodeficiency virus (HIV) qualitative test for the presence of HIV antigen and antibodies....

    Read More
  • Introduction of new PCR Gastrointestinal Pathogen Panel (5/7/13)

    Solstas Lab Partners is pleased to announce the addition to our testing menu of the first FDA-cleared multiplexed nucleic acid test (NAT) that can simultaneously detect 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample (Gastrointestinal Pathogen Panel (GPP))....

    Read More
  • Specimen Handling changes (4/26/13)

    Solstas Lab Partners would like to draw your attention to a specimen processing and transport change for the PLAC test - Solstas test Code 23254. Please read the instructions below carefully and refer any questions to our Client Services Department at 1-888-664-7601....

    Read More
  • Standardized Microbiology Culture Collection Swabs (4/16/13)

    Solstas Lab Partners is pleased to announce the availability and change of the conventional microbiology collection swab to the eSwab collection and transport system....

    Read More
  • Stool Culture with E.coli Shiga Toxin 1 & 2 Detection (3/28/13)

    Shiga toxin--producing E.coli (STEC) causes approximately 100,000 illnesses, 3,000 hospitalizations, and 90 deaths annually in the United States. Most reported STEC infections in the United States are caused by E.coli O157:H7, with an estimated 73,000 cases occurring each year. Non-O157 STEC bacteria also are important causes of diarrheal illness in the United States;...

    Read More
  • QuantiFERON-TB Gold Test for M. tuberculosis reactivity (2/11/13)

    Solstas Lab Partners is pleased to announce the availability of the QuantiFERON -TB Gold Interferon Gamma Release Assay (IGRA) for the detection of Mycobacterium tuberculosis (MTB) reactivity. The test will be performed at the Greensboro, N.C., reference laboratory and reported within 3 days of specimen receipt. We are pleased to offer this advanced test for MTB exposure screening that provides an alternative to the conventional purified protein (PPD) skin test....

    Read More
  • Conversion Corporate Reference and Critical/Alert Ranges (1/2/13)

    Effective Jan 1, 2013 Solstas STAT testing facilities will adopt the following Corporate Reference Ranges and Critical and Alert Values...

    Read More
  • Methylmalonic Acid Testing (12/3/12)

    Effective November 26, 2012, Solstas Lab Partners announced the availability of testing for methylmalonic acid (MMA) at our Greensboro, NC reference laboratory. This testing will be performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to assist in the assessment of patients with signs and symptoms associated with cobalamin (Vitamin B12) deficiency leading to methylmalonic acidemia. Several studies have suggested that the determination of serum or urinary methylmalonic acid may be a more reliable marker of cobalamin deficiency than direct cobalamin determination....

    Read More
  • Prescription Management Program (PMP) Changes (11/8/12)

    Solstas Lab Partners is pleased to announce the introduction of new liquid chromatographytandem mass spectrometry equipment that enables some of the most advanced toxicology testing possible in our toxicology departments. This improved clinical laboratory testing technology now provides improved analytical sensitivity and allows lower cutoffs to be used for drug screening. Effective November 26, 2012, Solstas will enhance our Prescription Management Program (PMP) by revising some of the drug of abuse testing cutoffs to improved, lower detection limits....

    Read More
  • Vaginitis Testing (10/31/12)

    Vaginitis is an inflammation of the vagina, and can affect women of all ages. Vaginitis symptoms and treatment differ depending on the causative agent: bacteria, the protozoan parasite Trichomonas vaginalis, yeast, an allergen, or a decrease in estrogen. Of the millions of cases of vaginitis each year, most are caused by bacterial vaginosis (about 40% to 50%), followed by yeast infections (20% to 25%) and then trichomoniasis (15% to 20%)....

    Read More
  • Test Offered by Solstas for Improved Cardiovascular Care: NT-proBNP (10/22/12)

    Solstas Lab Partners is pleased to announce the addition of NT-proBNP (Brain Natriuretic Peptide) to our clinical testing menu. NT-proBNP may provide additional clinical information in the diagnosis and evaluation of patients suspected of having congestive heart failure. NT-proBNP has also been described in the risk stratification of patients with acute coronary syndrome and as an aid in the assessment of increased risk of cardiovascular events and mortality in patients at risk for heart failure who have stable coronary artery disease....

    Read More
  • Solstas Announces Changes in Cardiac Tests (10/16/12)

    Effective October 1, 2012, Solstas Lab Partners® implemented the following changes in two cardiovascular laboratory tests...

    Read More
  • Update in Algorithm for Calculation of eGFR (10/10/12)

    Solstas Lab Partners®is pleased to announce that the algorithm that is being used for the calculation of eGFR (estimated Glomerular Filtration Rate) for the assessment of asymptomatic chronic kidney disease was updated to the newer CKD-EPI (Chronic Kidney Disease-Epidemiology Collaboration) equation, effective October 15, 2012....

    Read More
  • Solstas First to Power North Carolina HIE (5/14/12)

    Solstas Lab Partners and North Carolina Health Information Exchange (NC HIE) have agreed to collaborate on the state's first laboratory-supported health information exchange. ...

    Read More
  • Solstas Brings 3 More Labs Aboard (7/15/11)

    The three regional facilities give Solstas a significant launch pad for growth throughout the Southeast. ...

    Read More

Client Announcements

  • Solstas' Response to Fungal Meningitis Outbreak (10/5/12)

    As you are undoubtedly aware, a rare form of fungal meningitis has caused the death of at least 5 people in the Southeast and has sickened more than 30 patients across six states. There have been 25 cases and 3 deaths in Tennessee, four cases and one death in Virginia, two cases and one death in Maryland, two cases in Florida, one case in North Carolina, and one case in Indiana....

    Read More